Wyeth Reports Earnings Results for the 2007 Third Quarter and First N...( * 2007 Third Quarter Worldwide Net Re...),Health

* 2007 Third Quarter Worldwide Net Revenue Increased 9% to $5.6 Billion and Reported Diluted Earnings per Share Decreased 1% to $0.84. Diluted Earnings

per Share, Before Certain Significant Items, Increased 7% to $0.90 * 2007 First Nine Months Worldwide Net Revenue Increased 10% to $16.6 Billion and Reported Diluted Earnings per Share Increased 7% to $2.63. Diluted Earnings per Share, Before Certain Significant Items, Increased 10%

to $2.74 * $5 Billion Share Repurchase Program Announced. Dividend to Stockholders

Increased by 7.7%

MADISON, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today reported results for the 2007 third quarter and first nine months ending September 30, 2007. Worldwide net revenue increased 9% to $5.6 billion for the 2007 third quarter and 10% to $16.6 billion for the 2007 first nine months. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 6% for the 2007 third quarter and 7% for the 2007 first nine months.

"Outstanding 2007 third quarter performance was driven by revenue growth from our broad portfolio of drugs, vaccines and biotech products," said Robert Essner, Chairman and Chief Executive Officer. "We are on track to achieve annual sales of more than $1 billion in seven product categories. In addition, we are seeing excellent growth in all divisions of the Company, with our Fort Dodge Animal Health division projected to reach $1 billion in annual sales for the first time ever."

2007 Third Quarter and First Nine Months Product Highlights

Set forth below is a table of net revenue for Wyeth's principal products for the 2007 third quarter and first n
'/>"/>